Smoking Cessation and Clinical Outcomes in Young Patients Undergoing Endovascular Treatment for Critical Limb Ischemia  by de Donato, Gianmarco et al.
JOURNAL OF VASCULAR SURGERY
64S Abstracts May Supplement 2013as initial indication for treatment who received BM stent
were less likely to develop critical limb ischemia after stent
occlusion (OR, 0.25; P ¼ .016).
Conclusions: Compared to BM stent use of CS in the
treatment of advanced SFA and popliteal lesions is associ-
ated with higher primary patency rates. Patients are more
likely to advance from claudication to critical limb ischemia
after failure of a covered stent.
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Gender Differences in the Long-Term Outcomes of
Infrainguinal Arterial Revascularization: Retrospective
Multicenter Analysis
Kei Ichihashi, Yoshimitsu Soga. Cardiology, Kokura
Memorial Hospital, Fukuoka, Japan
Objectives: The purpose of this study is to evaluate
the gender differences in the long-term outcomes of
infrainguinal revascularization, in multi-center experience.
Methods: This study was multicenter retrospective
analysis from January 2004 to December 2009. 1001 limbs
(696 men; group1 and 305 women; group2) underwent
infrainguinal arterial revascularization; endovascular therapy
and bypass surgery. Male and female group were compared
in terms of primary patency and secondary patency.
Patencies were assessed by either duplex ultrasound or angi-
ography, analyzed by Kaplan-Meier estimation and
compared by the log rank test.
Results: There were no differences in all cause death,
MACE and MALE between two groups. At 6 years, theFig.primary patency rate were 48.2% (male group) and 32.1%
(female Group) (P ¼ .0001), secondary patency rates
were 80.5% and 68.9% (P ¼ .0008).
Gender (HR, 1.40; 95% CI, 1.15 to 1.73; P ¼ .001)
and critical limb ischemia (HR, 1.61; 95% CI, 1.16 to
2.23) were risk factors of infrainguinal artery restenosis.
Conclusions: Signiﬁcant sex differences exist with re-
gard to the outcomes in infrainguinal arterial revascularization.
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Critical Limb Ischemia
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Alessandro Cappelli, Carlo Setacci. Department of
Medicine, Surgery and Neuroscience, Vascular and
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Objectives: Endovascular treatment is being offered
more and more to young patients with critical limb
ischemia (CLI), but patency rates and outcomes have
been reported as modest. This study assesses outcomes of
endovascular revascularization in young CLI patients
according to their smoking attitude.
Methods: Outcomes after endovascular treatment
performed from 2005 to 2012 were retrospectively revised
in patients aged <50 years at the time of revascularization.
Risk of reintervention and limb loss were assessed accord-
ing to timing of smoking cessation, adjusted for clinical
confounders.
Results: Percutaneous angioplasty was performed on
112 limbs of 86 patients with CLI (Rutherford category
4 ¼ 19.7%; 5 ¼ 70.5%; or 6 ¼ 9.8%). Initial technical
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51 months.
Overall, limb loss at 2 years was 8.9% (n ¼ 10), but
10.2% in patients who had smoked (9 of 88) vs 4.2%
in those who had not (1 of 24). Compared with the latter,
risk-adjusted odds ratios were 3.3 (P ¼ .04), 2.8 (P ¼ .05),
and 1.6 (P ¼ .1) for those whose timing of smoking cessa-
tion was categorized as current smoker, quit just after inter-
vention, and quit 3 months preoperatively.
Occurrence of reintervention at 2 years was 22.3% (n ¼
25) overall, but 25% in patients who had smoked (22 of
88) vs 12.5% in those who had not (3 of 24). Compared
with the latter, risk-adjusted odds ratios were 4.3 (P ¼
.01), 2.3 (P ¼ .03), and 1.2 (P ¼ .1) for those whose
timing of smoking cessation was categorized as above.
Conclusions: Direct effects of smoking on peripheral
arterial reactivity are considered to be responsible for
premature failure after intraluminal treatment of CLI in
young patients. Smoking cessation is presumed to be bene-
ﬁcial before endovascular treatment.
Risks of limb loss and reintervention after intervention
are increased by smoking and mitigated gradually by pre-
operative cessation.
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Impact of Chronic Kidney Disease on the Effectiveness
of Peripheral Endovascular Interventions
Heather L. Gill, Jeffrey J. Siracuse, Peter H. Connolly,
John K. Karwowski, Harry L. Bush, Darren B. Schneider,
Andrew J. Meltzer. Weill Cornell Medical College,
New York, NY
Objectives: Patients with severe CKD were excluded
from the SVS objective performance goals (OPG) deriva-
tion cohort due to established poor surgical outcomes in
this group. We examine the impact of diminished creati-
nine clearance (CrCl) on the long-term outcomes of
peripheral endovascular interventions.
Methods: Retrospective review of prospectively col-
lected institutional outcomes data (2006-2012) included
calculation of CrCl and stratiﬁcation by chronic kidney
disease (CKD) class. Outcomes among those with mild
(class 1, 2) moderate (class 3), and severe (class 4, 5) CKD
were compared using SVSOPG outcomemetrics. Multivar-
iate models were developed to identify risk factors for poor
outcome and speciﬁcally assess the impact of CKD.
Results: 454 patients underwent treatment of 523
limbs for claudication (56%), rest pain (12%), or tissue
loss (32%). Over 77% of patients had abnormally low
CrCl, with moderate CKD noted in 37% and severe
CKD in 13%. Increasing CKD class was associated with
worse outcomes across all outcome metrics by crude
survival analysis. Following adjustment for all other risk
factors, the impact of severe CKD was independently asso-
ciated with reduced overall survival (HR, 2.69; 95% CI,
1.70-4.26; P < .001), amputation-free survival (HR,
3.15; 95% CI, 2.04-3.86; P < .001), limb salvage (HR,4.35; 95% CI, 1.50-12.33; P ¼ .006), major adverse
limb events (HR, 2.07; 95% CI, 1.02-4.20; P ¼ .04),
freedom from reintervention and amputation (HR, 1.82;
95% CI, 1.12-2.94; P ¼ .015) and freedom from reinter-
vention, amputation, and stenosis (HR, 1.58; 95% CI,
1.02-2.46; P ¼ .041).
Conclusions: Moderate and severe CKD are highly
prevalent among patients with PAD. While severe CKD
adversely affects long-term outcomes after ET as well as
surgical bypass, quantiﬁcation of the impact of reduced
CrCl on survival- and limb-based metrics may enhance
risk adjustment for comparative effectiveness research and
improve patient-centered clinical decision-making.
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Long-Term Clinical Outcome and Predictors After
Femoropopliteal Stenting With Self-Expandable
Nitinol Stent for Critical Limb Ischemia
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Hospital, Amagasaki, Japan
Objectives: The objectives is to investigate the long-
term efﬁcacy of FP stenting with nitinol stents for CLI.
Methods: This study was a multicenter retrospective
study. From January 2004 to December 2011, 598 consec-
utive patients (865 limbs; mean age 74.4 6 10.3 years;
61.5% male) who underwent successful FP stenting with
self-expandable nitinol stents for de novo lesions, CLI
were retrospectively analyzed. Outcome measures were
primary patency (PP), secondary patency (SP), overall
survival (OS), amputation free survival (AFS), limb salvage
(LS), major adverse cardiovascular events (MACE; all-
cause death, myocardial infarction and stroke), MALE
(repeat revascularization for the limb or major amputation
[deﬁned as above-the-ankle amputation]). Restenosis was
deﬁned as >2.4 of peak systolic velocity ratio by duplex
or >50% stenosis by angiogram. Primary patency was
deﬁned as treated vessels without restenosis and repeat
revascularization. Secondary patency was deﬁned as target
vessels that become totally occluded and are reopened by
repeat revascularization.
Results: Sixty-six percent of the patients had diabetes,
and 39% were on hemodialysis. The mean follow-up period
was 19.1 6 17.2 months. PP was 77.0%, 59%, and 46.7%,
and SP was 93.9%, 87.9%, and 80.3% at 1, 3, and 5 years,
respectively. OS was 83.4%, 63.1%, and 49.6%, and AFS
was 78.5%, 59.9%, 46.7%, and LS was 93.3%, 90.8%,
90.8%, and freedom from MACE was 82.1%, 61.5%,
45.7%, and freedom from MALE was 77.9%, 71.9%,
48.8%, respectively. Onmultivariate analysis by Cox propor-
tional hazard ratio, female gender (hazard ratio [HR], 1.4;
P ¼ .048), body mass index (HR, 1.05; P ¼ .04), cilostazol
administration (HR, 0.63; P ¼ .005), and TASC II class
C/D (HR, 1.67; P¼ .007) were the independent predictors
of primary patency after successful FP stenting.
